Q2 results preview: Lower input costs may help pharma margins | Health news

Analysts expect pharmaceutical companies to post sales growth of 10-11% in the second quarter of this fiscal year, while ebitda (earnings before interest, taxes, depreciation and amortization) margins are expected to improve about 110 basis points.

Ebitda improvement will be led by lower input costs as active pharmaceutical ingredient (API) prices are 5-15% lower year-on-year (YoY).

Axis Capital said sales growth would be around 10%, of which growth in the India market would be around 11%. And the United States (US) market would see a 4 per